7:50 am Morning Refreshments

8:50 am Chair’s Opening Remarks

DEVELOPING NOVEL AI MODELS TO DETECT RETINAL DISEASE BIOMARKERS FOR FASTER, MORE ACCURATE & OBJECTIVE DATA ANALYSIS & PATIENT STRATIFICATION

9:00 am AI in the Management of AMD from Clinical Trial to Real World

Synopsis

  • The path of development, validation and regulatory approval for fully-automated algorithms
  • Introduction of novel biomarkers and endpoints into clinical studies in the era of AI-empowered reading centers
  • Using automated precision tools for screening, monitoring and prediction in clinical routine

9:30 am Panel Discussion: Improving Patient Care with the Help of Personalised Medicine Through AI for the Diagnosis & Optimization of the Right Patients for Clinical Trials

  • Ursula Schmidt-Erfurth Professor & Chair, Ophthalmology & Optometry, Medical University of Vienna
  • Nadia Waheed Assistant Professor, Ophthalmology, Boston Image Reading Center
  • Stephen Poor Executive Director & Head of Global Program Clinical, Novartis

Synopsis

  • Understanding characteristics of retinal imaging and artificial intelligence that may help identify the right patients for clinical trials
  • Utilizing different imaging tools for treatment and management of patients – different imaging modalities and which ones are more appropriate for different Ophthalmic disease states
  • Using AI to improve patient care by sequencing data and linking imaging databases to diagnosis the right patients for the right type of treatment

10:30 am Morning Break

11:30 am Using Advanced Image Analysis for More Efficient Drug Development for Retinal Diseases

  • Heiko Niessen Global Head of Translational Medicine & Clinical Pharmacology, Retinal Health, Boehringer Ingelheim

Synopsis

  • Examining the value of AI in data analysis along drug development
  • Linking information extracted from AI-based predictions to better define patient population, earlier disease detection and faster therapeutic intervention
  • Exploring BI partnerships to leverage AI-based predictive analytics

12:00 pm Discussing the Capabilities of Current Modalities to Image Geographic Atrophy & Reviewing the Future of AI

  • Divya D’Souza Executive Director - Clinical Development, Astellas Pharma

Synopsis

  • Current endpoints for geographic atrophy, measuring death of retinal pigment and photo receptor cells
  • Exploring the role of imaging biomarkers to predict lesion growths and functional outcomes
  • Recent advancements in imaging GA by using AI algorithms to measure the extent of dead photoreceptor cells and identifying the right patients for treatment in clinical trials

12:30 pm Artificial Intelligence for Clinical Trials in Retinal Diseases

Synopsis

  • Identifying challenges and hurdles in clinical trials for drug development that can be positively impacted by AI-based tools
  • Using AI-based tools to extract scientific insights, enable better disease characterization, and predict disease progression
  • Considerations on implementation of AI-based tools in clinical trials

1:00 pm Lunch & Networking Break

UNCOVERING NOVEL IMAGING & BIOMARKER TECHNOLOGIES & IMPROVED DATA ANALYSIS ACROSS MULTI-MODAL IMAGING DATA

2:00 pm Demonstrating How Novel Imaging & Biomarker Technologies Enhance Early Clinical Interpretation

  • David Esposito President & Chief Executive Officer, ONL Therapeutics

Synopsis

  • Sharing clinical data from trials for Dry AMD, retinal detachment and glaucoma
  • Assessing the practical application of imaging technologies, such as AST and DARC, in clinical development
  • Determining the regulatory pathway to support broader application of novel imaging technologies

2:30 pm Multiplex Analysis of Clinical Imaging & Biomarker Data to Validate Novel Endpoints for Diabetic Retinopathy

Synopsis

  • Discussing the diagnostic value of ocular fluid biomarkers
  • Assessing the value of multimodal imaging in diabetic retinopathy
  • Planning phase III clinical studies diabetic retinopathy

CROSS-UTILIZATION OF RETINAL IMAGING DEVICES FOR DIAGNOSIS OF NEUROLOGICAL & DISORDERS

3:00 pm Utilizing Retinal Imaging for Earlier Detection & Disease Progression of Neurological Disorders

  • Tara DeSilva Associate Professor, Cleveland Clinic Taussig Cancer Institute

Synopsis

  • Assessing the correlation between OCT with MRI in the brain to predict neurodegeneration in multiple sclerosis
  • Using the visual assessments for preclinical testing for neuroprotective strategies in multiple sclerosis
  • Exploring the relevance of visual imaging for early detection of multiple sclerosis

3:30 pm Chair’s Closing Remarks & End of Conference